1. J.L. Li, T. Zhang, Di Wu, C. He, H.X. Weng, T.D. Zheng, J. Liu, H. Yao, J.C. Chen*, Y.S. Ren*, Z.Y. Zhu, J.Y. Xu*, S.T. Xu*. Palladium-mediated bioorthogonal system for prodrug activation of N-benzylbenzamide-containing tubulin polymerization inhibitors for the treatment of solid tumors. J. Med. Chem. 2024, 67, 19905-19924.

2. H.J. Zhu, W.J. Zhu, Y. Liu, T. Gao, J.J. Zhu, Y.C. Tan, H. Hu, W.H. Liang, L.Y. Zhao, J. Chen, Z.Y. Zhu, J.C. Chen*, J.Y. Xu*, S.T. Xu*. Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo. Eur. J. Med. Chem. 2023, 257, 115529.

3. Z.W. Tang, C. Chen, C. Zhou, Z.Y. Liu, T. Li, Y. Zhang*, Y.Y. Feng, C.L. Gu, S.J. Li, J.C. Chen*. Insights into tumor-derived exosome inhibition in cancer therapy. Eur. J. Med. Chem.2025, 285, 117278.

4.  L. Chen, B.X. Zhang, P.J. Zhou, Y.P. Duan, C. He, W.Y. Zhong, T.Y. Wang, S.T. Xu, J.C. Chen*, H. Yao*, J.Y. Xu*. Design, synthesis, and biological evaluation of novel HPK1 inhibitors possessing 3-cyano-quinoline moiety. Bioorg. Chem. 2024, 153, 107814.

5.  C. Chen, Y.Y. Feng, C. Zhou, Z.Y. Liu, Z.W. Tang, Y. Zhang*, T. Li, C.L. Gu, J.C. Chen*. Development of natural product-based targeted protein degraders as anticancer agents. Bioorg. Chem. 2024, 153, 107772.

6 . Z.Y. Liu, T. Li, C.L. Gu, C. Chen, Z.W. Tang, Y.Y. Feng, C. Zhou, J.Y. Xu*, J.C. Chen*. Novel agents derived from natural product β-elemene: A second round of design and synthesis to enhance antitumor properties. Bioorg. Med. Chem. 2025,121, 118129.

7.  J.C. Chen*, Y.P. Duan, K. Yang, J.H. Wang, J.J Yang, C.L. Gu, S.L. Wang, Z.Y. Zhu, E.H. Liu*, J.Y. Xu*. Design, synthesis and biological evaluation of novel 9-N-substituted-13-alkylberberine derivatives from Chinese medicine as anti-hepatocellular carcinoma agents. Bioorg. Med. Chem. 2023, 79, 117156.

8. J.C. Chen*, Y.P. Duan, X.X. Yu, J.R. Zhong, J. Bai, N.G. Li*, Z.Y. Zhu, J.Y. Xu*. Development of novel 9-O-substituted-13-octylberberine derivatives as potential anti-hepatocellular carcinoma agents. J. Enzyme Inhib. Med. Chem.2022, 37, 2423-2433. 

9 .J.C. Chen, E. Miliordos, M. Chen*. Highly diastereo- and enantioselective synthesis of 3,6’-bisboryl-anti-1,2-oxaborinan-3-enes: an entry to enantioenriched homoallylic alcohols with a stereodefined trisubstituted alkene.Angew. Chem. Int. Ed. 2021, 60, 840-848.

10. J.C. Chen, S. Gao, M. Chen*. Cu-catalyzed C-C bond formation of vinylidene cyclopropanes with carbon nucleophiles. Chem. Sci. 2019, 10, 10601-10606.

1.国家自然科学基金青年项目(82304285)，新型微管蛋白秋水仙碱结合位点和PARP-1双靶抑制剂的设计、合成及抗三阴性乳腺癌研究，2024/01-2026/12，主持，30万

2.江苏特聘教授人才项目(013038023001)，天然来源先导化合物的发现与成药性优化研究，2021/10-2024/10，主持，100万

3.南京中医药大学高层次人才项目(013038023001P)，2021/10-2024/10，主持，100万

4.南京市留学人员科技创新项目B类, 2022/10-2023/10，主持，5万

1. J.L. Li, T. Zhang, Di Wu, C. He, H.X. Weng, T.D. Zheng, J. Liu, H. Yao, J.C. Chen*, Y.S. Ren*, Z.Y. Zhu, J.Y. Xu*, S.T. Xu*. Palladium-mediated bioorthogonal system for prodrug activation of N-benzylbenzamide-containing tubulin polymerization inhibitors for the treatment of solid tumors. J. Med. Chem. 2024, 67, 19905-19924.

2. H.J. Zhu, W.J. Zhu, Y. Liu, T. Gao, J.J. Zhu, Y.C. Tan, H. Hu, W.H. Liang, L.Y. Zhao, J. Chen, Z.Y. Zhu, J.C. Chen*, J.Y. Xu*, S.T. Xu*. Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo. Eur. J. Med. Chem. 2023, 257, 115529.

3. Z.W. Tang, C. Chen, C. Zhou, Z.Y. Liu, T. Li, Y. Zhang*, Y.Y. Feng, C.L. Gu, S.J. Li, J.C. Chen*. Insights into tumor-derived exosome inhibition in cancer therapy. Eur. J. Med. Chem.2025, 285, 117278.

4.  L. Chen, B.X. Zhang, P.J. Zhou, Y.P. Duan, C. He, W.Y. Zhong, T.Y. Wang, S.T. Xu, J.C. Chen*, H. Yao*, J.Y. Xu*. Design, synthesis, and biological evaluation of novel HPK1 inhibitors possessing 3-cyano-quinoline moiety. Bioorg. Chem. 2024, 153, 107814.

5.  C. Chen, Y.Y. Feng, C. Zhou, Z.Y. Liu, Z.W. Tang, Y. Zhang*, T. Li, C.L. Gu, J.C. Chen*. Development of natural product-based targeted protein degraders as anticancer agents. Bioorg. Chem. 2024, 153, 107772.

6 . Z.Y. Liu, T. Li, C.L. Gu, C. Chen, Z.W. Tang, Y.Y. Feng, C. Zhou, J.Y. Xu*, J.C. Chen*. Novel agents derived from natural product β-elemene: A second round of design and synthesis to enhance antitumor properties. Bioorg. Med. Chem. 2025,121, 118129.

7.  J.C. Chen*, Y.P. Duan, K. Yang, J.H. Wang, J.J Yang, C.L. Gu, S.L. Wang, Z.Y. Zhu, E.H. Liu*, J.Y. Xu*. Design, synthesis and biological evaluation of novel 9-N-substituted-13-alkylberberine derivatives from Chinese medicine as anti-hepatocellular carcinoma agents. Bioorg. Med. Chem. 2023, 79, 117156.

8. J.C. Chen*, Y.P. Duan, X.X. Yu, J.R. Zhong, J. Bai, N.G. Li*, Z.Y. Zhu, J.Y. Xu*. Development of novel 9-O-substituted-13-octylberberine derivatives as potential anti-hepatocellular carcinoma agents. J. Enzyme Inhib. Med. Chem.2022, 37, 2423-2433. 

9 .J.C. Chen, E. Miliordos, M. Chen*. Highly diastereo- and enantioselective synthesis of 3,6’-bisboryl-anti-1,2-oxaborinan-3-enes: an entry to enantioenriched homoallylic alcohols with a stereodefined trisubstituted alkene.Angew. Chem. Int. Ed. 2021, 60, 840-848.

10. J.C. Chen, S. Gao, M. Chen*. Cu-catalyzed C-C bond formation of vinylidene cyclopropanes with carbon nucleophiles. Chem. Sci. 2019, 10, 10601-10606.

1.陈继超, 徐进宜, 曹鹏, 段易平, 李念光, 朱哲英，于小轩，钟佳柔. 9-N-胺烷基-13-烷基(-8,9-环化)小檗碱衍生物及其制备方法和用途. 授权日期2023.10.27. 专利号ZL202210525547.8

2.陈继超, 徐进宜, 曹鹏, 李念光, 朱业锦, 仲崇金, 段易平. 9-O-胺烷基-13-烷基双取代小檗碱衍生物及其制备方法和用途. 授权日期2023.09.22. 专利号ZL202111244695.4

3.徐进宜,陈继超, 王天雨, 徐盛涛, 朱哲英, 王佳, 姚和权, 林爱俊, 谢唯佳. 一氧化氮供体型原小檗碱类衍生物及其制备方法和用途. 授权日期2018.10.16. 专利号ZL201710164003.2

4.徐进宜, 陈继超, 王天雨, 许海, 王若研, 许婷, 陈晓彤. 异丙醇胺取代β-榄香烯衍生物及其制备方法和用途. 授权日期2018.12.18. 专利号ZL201710038987.X

5. 徐进宜, 陈继超, 王天雨, 许海, 王若研, 许婷, 陈晓彤. β-榄香烯二聚体衍生物、其制备方法及其用途. 授权日期2018.07.17. 专利号ZL201710038980.8

6. 徐进宜,陈继超, 王天雨, 许海, 王若研, 许婷, 陈晓彤. 一氧化氮供体型β-榄香烯衍生物及其制备方法和用途. 授权日期2018.03.09. 专利号ZL201710066664.1